SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Marksans Pharma - Quaterly Results

19 May 2025 Evaluate
The sales surged to Rs. 2993.57 millions, up 32.93% for the March 2025 quarter as against Rs. 2251.96 millions during the corresponding quarter previous year.Profit saw a slight increase of 13.93%to Rs. 375.91  millions from Rs. 329.94 millions.Operating profit for the quarter ended March 2025 rose to 583.91 millions as compared to 460.99 millions of corresponding quarter ended March 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 2993.57 2251.96 32.93 11743.74 8532.73 37.63 11743.74 8532.73 37.63
Other Income 78.17 121.94 -35.89 698.34 620.73 12.50 698.34 620.73 12.50
PBIDT 583.91 460.99 26.66 2738.85 2020.08 35.58 2738.85 2020.08 35.58
Interest 3.11 2.28 36.40 11.74 9.88 18.83 11.74 9.88 18.83
PBDT 580.80 458.71 26.62 2727.11 2010.20 35.66 2727.11 2010.20 35.66
Depreciation 81.77 74.72 9.44 294.52 291.28 1.11 294.52 291.28 1.11
PBT 499.03 383.99 29.96 2432.59 1718.92 41.52 2432.59 1718.92 41.52
TAX 123.12 54.05 127.79 549.87 381.34 44.19 549.87 381.34 44.19
Deferred Tax 7.54 -31.08 -124.26 28.43 6.78 319.32 28.43 6.78 319.32
PAT 375.91 329.94 13.93 1882.72 1337.58 40.76 1882.72 1337.58 40.76
Equity 453.16 453.16 0.00 453.16 453.16 0.00 453.16 453.16 0.00
PBIDTM(%) 19.51 20.47 -4.71 23.32 23.67 -1.49 23.32 23.67 -1.49

Marksans Pharma Share Price

176.85 -2.70 (-1.50%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×